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Abstract
Significant atrial septal defects (ASD) are closed, surgically 
or through a transcatheter device, in order to avoid pulmonary 
hypertension in late life. A patent foramen ovale (PFO) may 
need to be closed because of transient shunt reversal resulting 
in transient ischaemic events or stroke. We report the Maltese 
experience to date in transcatheter closure of these defects. A 
total of 46 ASDs and 51 PFOs have been successfully closed at 
our unit (total 97), with very low complication rates, rates that 
compare very favourably with results from larger international 
centres.
Introduction
Atrial septal defects
Atrial septal defects (ASDs) account for 10% of all 
congenital heart disease and are defined as congenital structural 
deficiencies of the atrial septum.1 The most common site of the 
structural deficiency is in the ostium secundum (fossa ovalis). 
The haemodynamic and pathological consequences of an ASD 
are dependent on the magnitude and duration of the left to 
right shunt, and on the resulting response of the pulmonary 
vascular bed. Large shunts cause right atrial and right ventriclar 
enlargement and the excessive flow into the pulmonary vascular 
bed may eventually result in fibrotic and vascular occlusive 
disease with irreversible pulmonary arterial hypertension; this 
usually occurs in adult life, with increased morbidity and early 
mortality.2 Lesions causing significant shunts (defined as a 
pulmonary to systemic blood flow ratio (Qp/Qs) of  > 1.5) are 
therefore closed in early childhood or whenever a diagnosis is 
made in later years. 
Patent foramen ovale
In utero, the foramen ovale serves as a physiologic passage 
for right-to-left shunting. After birth, increased left atrial flow 
and pressure result in functional closure of the foramen, and 
this is usually followed by anatomical closure. However, a 
probe-patent foramen ovale has been shown to persist in up 
to 25-35% of adults in autopsy series.3 This can be confirmed 
in vivo by contrast echocardiography, wherein a persistently 
patent foramen ovale (PFO) can be detected in 5-20% of adults.4 
A PFO is usually flap-like potential opening between the atrial 
septum primum and secundum in the fossa ovalis and not an 
actual gap in the interatrial septum (Figure 1).
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Table 1: Age by lesion (ASD/PFO) and gender
    ASD   PFO
Age All Female Male All Female Male
Mean 23 26 15 46 47 46
CL (95%) 5.4 6.9 7.3 4.2 8.1 4.9
Median 14 20 9 49 49 46
SD 18 19 12 15 17 13
Min 4 4 6 7 7 17
Max 66 66 43 71 71 69
n 46 33 13 51 20 31
Several studies have confirmed an association between 
the presence of a PFO and the risk for paradoxical embolism 
which can result in transient ischaemic episodes (TIA), stroke 
or peripheral embolisation.5,6 A retrospective multicenter study 
demonstrated an annual risk of 1.2% to sustain a recurrent TIA, 
and of 3.4% to suffer a recurrent stroke or TIA despite medical 
treatment with oral anticoagulants or antiplatelet drugs in 
patients with PFO and cryptogenic stroke.6-8
PFO and ASD closure has been performed in Malta since 
1998, comprising a local team, a visiting cardiologist, and an 
anaesthetist, with surgical backup.
This paper details the protocol that is followed in patient 
selection, and subsequent intervention and follow-up for both 
ASD and PFO. We also outline our results and complications 
to date.
Methods
Protocol
The protocol followed is shown in Figure 2. Patients 
presenting to the Neurology Department with TIA or stroke 
are assessed, particularly for risk factors predisposing to 
cerebrovascular disease. Such factors include increasing age, 
a history of diabetes mellitus, hypertension, hyperlipidaemia, 
atherosclerotic disease (including ischaemic heart disease and 
peripheral vascular disease), valvular heart disease and a history 
of smoking, alcohol, or use of the oral contraceptive pill. 
An ECG is performed to establish whether there is 
hypertrophy or arrhythmias. Routine blood tests include 
random blood glucose and a lipid profile. Carotid artery imaging 
is performed with Doppler ultrasonography or magnetic 
resonance angiography to exclude carotid artery stenosis. In 
cases of cryptogenic stroke or TIA, particularly in young patients 
(< 50 years) with none of the above risk factors identified, further 
investigations are performed and these include the exclusion 
of thrombophilic conditions including deficiency of protein 
C and S, antithrombin III, serum fibrinogen, anti-cardiolipin 
antibodies, serum homocysteine, genetics for Factor V Leiden 
deficiency, 660210A mutation in the Coagulation Factor II Gene 
and MTHFR Genotype C677T mutation.
Echocardiographic assessment is also done as shown 
in Figure 2. The finding of a PFO where none of the other 
obvious risk factors are present is considered to be a potential 
contributor to cerebral ischaemic episodes, and patients are 
referred for closure.
The methodology followed locally for device closure has 
already been outlined in a previous paper.9
Patients
All patients who had interventional closure of ASD or 
PFO were obtained from the Maltese Paediatric Cardiology 
Database,10 and from a database maintained by the radiography 
section at the St. Luke’s Catheterization Suite for the period 
2002-2007.
Figure 1: The anatomy of a patent foramen ovale
Statistics
Statistical analysis was performed by Excel (summary 
statistics and 2-tailed t-tests). A p value of less than 0.05 was 
taken to represent a statistically significant result.
Results
A total of 46 ASDs and 51 PFOs have been successfully 
closed at our unit (total 97). A breakdown of lesion by age and 
gender is given in Table 1. There were no significant differences 
by age and gender for PFO but the male ASD population was 
significantly younger than the female ASD population (2-tailed 
t=2.0, p=0.013). The PFO population was significantly older 
than the ASD population (2-tailed t=1.9, p<0.01).
Five were closed with Helex (Gore, Flagstaff, Arizona) 
devices and all of the remainder were closed with Amplatzer ASO 
(atrial septal occluder) devices (AGA, Plymouth, Minnesota).
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There were some unusual cases in the series which included 
the following:
1. Two patients who had ASD closure with Amplatzer 
devices for residual cyanosis after neonatal treatment for 
critical pulmonary stenosis.11
2. One patient who had two septal defects and in whom 
closure involved the implantation of two separate 
Amplatzer devices in the same session.
3. There were two patients with recurrence of neurological 
events after PFO closure.  One of these (who had a 
Helex device) had a residual shunt documented by 
echocardiography and had closure of this residual shunt 
using a Amplatzer cribriform device. No shunt could be 
documented in the other case and therefore no action was 
taken.
Complications were few and included:
1. Amplatzer device detachment from the delivery wire 
while still within the delivery sheath. This was caused by 
a faulty loader. The sheath and device were removed and 
the same device was delivered through the same delivery 
system but using a new loading system.
2. Amplatzer device fully deployed in left atrium in two 
patients – this was recognized and the device was 
therefore pulled back into the sheath and redeployed 
correctly.
3. Amplatzer device everted itself within the sheath – the 
device was therefore removed and reloaded correctly into 
the sheath.
4. Four patients with transient atrial fibrillation after 
PFO closure (3 with Amplatzer devices and 1 with a 
Helex device) who settled down with medical treatment 
(cardioversion and/or amiodarone therapy for up to a 
total duration of 4 months).
In no patients was an emergency surgical procedure required 
e.g. for device embolisation or cardiac damage/perforation. 
There were no pericardial effusions associated with device 
placement. There was no mortality associated with device 
placement.
Discussion
Traditionally, including locally, ASDs, were surgically closed 
using cardiopulmonary bypass via a right atriotomy.12 Smaller 
defects are sutured closed while larger ones are patched with 
pericardium or synthetic material, with a current mortality of 
<1%.12 A wide variety of devices for transcatheter closure of ASDs 
have been developed in the past two decades and these allow 
over 80% of ASDs to be closed without open heart surgery, using 
the same indications as outlined above.13
The diagnosis of a PFO is made by contrast echocardiography 
(e.g. with injection of air agitated saline via the left arm), 
performing and then releasing a prolonged Valsalva maneouver. 
A PFO will be revealed by the subsequent transient reversal of 
the interatrial pressure gradient with contrast crossing from 
right to left atrium.14 Ischaemic stroke via paradoxical embolism 
in the setting of a PFO was first described in 1877,15 and should 
be suspected in the absence of a left-sided thromboembolic 
Figure 2: Protocol followed for closure of atrial septal defect and patent foramen ovale
TOE: transoesophageal echocardiogram
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source, the potential for right-to-left shunting or the detection of 
thrombus in the venous system or right atrium.16 Transcatheter 
closure of PFO is also possible by a variety of devices as outlined 
above for ASD.
We are unable to explain why male ASDs have been closed 
at a younger age than female ASDs. We can only hypothesise 
that males may have presented at an earlier age, although this 
was not supported in a literature search. Indeed, in a previous 
local publication, no significant gender difference had been 
shown.12 ASDs are naturally closed at a younger age than PFO as 
the latter manifest much later in life with an acute neurological 
presentation.
Our complication rates have been previously published,17 and 
are very low, comparing favourably with larger centres.18,19
ASD and PFO closure continue to be successfully undertaken 
at St. Luke’s Hospital to the benefit of the patients and with 
minimal risk. The advantages of local device placement are 
that patients benefit by not having to travel to a tertiary 
centre abroad, with attendant inconvenience, travelling and 
accommodation costs. 
This experience demonstrates the progression of 
developments in that new techniques and interventions are 
continually being developed and sooner or later become 
accepted by the international medical community. Such 
techniques are then taught to the local medical community by 
visiting consultants. 
Performing the procedure locally adds to the interventional 
experience of local operators and this familiarity, in turn, further 
benefits the spectrum of procedures carried out in Malta. For 
instance, through this experience, we also carry out closure of 
patent arterial duct and ventricular septal defects. 
This is one of the many areas of health care provided in Malta 
wherein the local service is kept abreast of developments in the 
international medical community.
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